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Inﬂammatory disease states (infection, arthritis) are associated with reduced drug oxidation by the cytochrome P450 3A
system. Many chemotherapy agents are metabolised through this pathway, and disease may therefore inﬂuence inter-individual
differences in drug pharmacokinetics. The purpose of this study was to assess cytochrome P450 3A function in patients with
advanced cancer, and its relation to the acute-phase response. We evaluated hepatic cytochrome P450 3A function in 40
patients with advanced cancer using the erythromycin breath test. Both the traditional C20min measure and the recently
proposed 1/TMAX values were estimated. The marker of acute-phase response, C-reactive protein and the pro-inﬂammatory
cytokines IL-6, IL-1b, TNFa and IL-8 were measured in serum or plasma at baseline. Cancer patients with an acute phase
response (C-reactive protein 410 mg l
71, n=26) had reduced metabolism as measured with the erythromycin breath test 1/
TMAX (Kruskal–Wallis Anova, P=0.0062) as compared to controls (C-reactive protein 410 mg l
71, n=14). Indeed,
metabolism was signiﬁcantly associated with C-reactive protein over the whole concentration range of this acute-phase marker
(r=70.64, Spearman Rank Correlation, P50.00001). C-reactive protein serum levels were signiﬁcantly correlated with those
of IL-6 (Spearman coefﬁcient=0.58, P50.0003). The reduction in cytochrome P450 3A function with acute-phase reaction
was independent of the tumour type and C-reactive protein elevation was associated with poor performance status. This
indicates that the sub-group of cancer patients with signiﬁcant acute-phase response have compromised drug metabolism,
which may have implications for the safety of chemotherapy in this population.
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Viral and bacterial infection, severe trauma and degenerative
diseases are known to cause signiﬁcant reductions in hepatic
drug clearance, mostly through decreased expression of drug-
metabolising cytochrome P450 enzymes (Morgan, 1997). This is
mediated largely through down-regulation of gene transcription
by the pro-inﬂammatory cytokines such as IL-6 and TNFa
(Muntane-Relat et al, 1995; Morgan, 1997; Guillen et al, 1998;
Pascussi et al, 2000). These cytokines also induce the synthesis
of acute-phase reactants, such as C-reactive protein, by the liver
(O’Riordain et al, 1999). This is usually accompanied by a
decreased synthesis of albumin and pre-albumin. Most
commonly, reduction in drug metabolism in the presence of
acute-phase reactants involves the cytochrome P450 3A family
(CYP3A), which is responsible for the metabolism of *60% of
drugs used in medicine. This includes many of those used in
cancer chemotherapy (e.g., taxanes, vinca alkaloids, camptothe-
cins, tamoxifen, etoposide and oxazaphosphorines (Kivisto et al,
1995)).
The manner in which patients tolerate chemotherapy in general
is remarkably unpredictable, and some experience signiﬁcant
morbidity leading to hospitalisation and, occasionally, mortality.
Pro-inﬂammatory cytokines and acute-phase reactants are elevated
in many patients with advanced cancer (Heys et al, 1998; Martin
et al, 1999) and there is, therefore, the possibility that part of the
inter-individual variability in drug clearance and toxicity could
relate to the effects of these cytokines on CYP3A expression
(Moreno et al, 1991; Craig et al, 1993; Chen et al, 1994;
Muntane-Relat et al, 1995; Morgan, 1997; Pascussi et al, 2000).
Further falls in CYP3A function may occur with age (Hunt et
al, 1990) and reduced hepatic drug clearance may contribute to
a greater risk of adverse events in elderly cancer patients (Yancik
et al, 1998).
Pharmacokinetic variability in the disposition of anticancer
drugs is responsible for a signiﬁcant proportion of inter-indivi-
dual variability in their activity and toxicity (Gurney, 1996).
Surprisingly, the impact on drug metabolism of the acute-phase
response that often accompanies cancer has not been explored in
this setting. Hence, the purpose of the presented study was to
estimate liver CYP3A function in patients with advanced cancer,
to examine its association with the acute-phase response and to
identify the key cytokines involved in the initiation of the latter.
Serum levels of basic ﬁbroblast growth factor (bFGF) and vascu-
lar endothelium growth factor (VEGF) have been shown to
correlate strongly with tumour stage and outcome in several
malignancies (Chen et al, 1999; Graeven et al, 1999; Ugurel et
al, 2001). These may predict for more aggressive tumours.
Hence, a secondary aim was to examine the relationship between
the acute-phase response and circulating levels of bFGF and
VEGF.
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Subjects
This was a prospective, single-centre study of the inﬂuence of
acute-phase response on drug metabolism in cancer patients. It
was open to all subjects 418 years of age with biopsy-proven,
advanced malignancy who were about to receive chemotherapy.
The entry criteria were: ECOG performance status (PS) 0-3,
neutrophils 43.0610
9 l
71, bilirubin 52.0 ULN (upper limit of
normal) and transaminases 52.56ULN unless evidence of liver
involvement (556ULN). The Ethics Committee of the Central
Sydney Area Health Service approved the study, and written
informed consent was obtained from all subjects.
Experimental protocol
Blood samples were collected for routine evaluation of haematolo-
gical and biochemistry parameters within 72 h prior to
administering the EBT. Serum samples were also collected for the
analysis of the acute-phase reactants C-reactive protein (CRP)
and a1 acid glycoprotein (AAG) as well as albumin and pre-albu-
min and frozen at 7708C until analysis. The latter were
performed by the Biochemistry Department of the Royal Prince
Alfred Hospital using standard turbidimetric and nephelometry
assays. Presence of an acute-phase response was deﬁned as CRP
410 mg l
71.
The cytokines IL-1b, IL-6, TNFa and IFNg were analysed in
serum and IL-8, VEGF and bFGF in plasma using commercial
ELISA kits (R&D, Minneapolis, MN, USA). Standard curves were
run with each batch and only values greater than the lowest stan-
dard were reported (415.6 pg ml
71 for IFNg, TNFa, VEGF;
431.2 pg ml
71 for IL-8; 43.9 pg ml
71 for IL-1b, 41p gm l
71
for bFGF and 43.13 pg ml
71 for IL-6).
The erythromycin breath test was performed as recently described
(Rivory et al, 2000). Brieﬂy, 4 mCi of
14C erythromycin (N-
methyl-
14C, 55 mCi mmole
71, NEN Life Science Products Inc,
Boston, MA, USA) was injected intravenously and breath samples
were collected into gas-tight balloons (Pytest
1, Ballard Medical
Products, Utah, USA) 5, 10, 15, 20, 25, 30 and 40 min later. These
were processed by bubbling the collected gas through a capture solu-
tion consisting of hyamine hydroxide 10X (Packard, Sydney, NSW,
Australia) in 50:50 methanol/ethanol v v
71 to which a trace of
phenolphthalein was added. After the addition of scintillant (Ultima
Gold
1, Packard, Sydney, NSW, Australia) and counting, the data
were expressed in terms of per cent of dose exhaled per minute at
each time point by assuming a CO2 output of 5 mmoles -
min
71 m
72 (Watkins et al, 1989). The widely used measure of
CYP3A activity, the ﬂux at 20 min (C20min), was recorded (Hirth
et al, 2000). In addition, the novel parameter, 1/TMAX, which corre-
lates with total drug clearance of erythromycin (Rivory et al, 2000)
was estimated from a ﬁtting of a bi-exponential equation to the data
as described recently (Rivory et al, 2000, 2001). In some cases, the
proﬁles were extremely ﬂat or had not reached a maximum at
40 min. In these cases, TMAX was set at 50 min.
Statistical analysis
The association between categorical (e.g. gender, ECOG) and
continuous variables (e.g. EBT results, cytokine concentrations)
was examined by Kruskal–Wallis Anova. Regression analyses
between continuous variables were performed with the Spearman
rank-order test.
The frequency distributions of CRP and AAG data were evalu-
ated using the Kolmogorov-Smirnov One Sample Test. All tests
were carried out using SYSTAT v 7.0.1 (SPSS Inc, Chicago, IL,
USA) and P50.05 was considered as signiﬁcant.
RESULTS
Between July 2000 and April 2001, a total of 40 subjects were inves-
tigated. These patients had mostly lung and breast cancer (see
Table 1) and ranged in age from 38 to 83, with a median of 64
years. There were similar numbers of males (n=21) and females
(n=19).
The erythromycin breath test results were found to vary widely
in this population. The median (and range in parentheses) for the
C20min measure was 0.050% min
71 (0.002–0.101) whereas it was
0.050 min
71 (0.02–0.12) for 1/TMAX. There was no signiﬁcant
effect of age or sex on either of the EBT parameters in this cancer
population (Spearman Rank-Order and Kruskal–Wallis Anova,
respectively).
Baseline serum CRP, AAG, albumin and pre-albumin were also
variable and are summarised in Table 2. Only two patients had
quantiﬁable serum TNFa (16.2, 18.5 pg ml
71), another two had
quantiﬁable IFNg (37.5, 77.9 pg ml
71), whereas most had quantiﬁ-
able serum IL-1b (median: 10.6 pg ml
71). IL-6 was quantiﬁable in
over half (n=33) with a median of 5.6 pg ml
71 (range: 53.2–
193.5 pg ml
71). VEGF was found to range from 532.1 to
1537 pg ml
71 with a median of 274.6 pg ml
71. The range
observed for bFGF was 51p gm l
71 to 12.2 pg ml
71.
When the cancer patients were divided into control
(410 mg l
71) and acute-phase response (410 mg l
71) groups
based on the upper normal limit of serum CRP, those in the
acute-phase group had an average 30% reduction in drug metabo-
lism (0.070+0.024 vs 0.049+0.022 min
71, respectively). This was
statistically signiﬁcant (P=0.0062, Kruskal–Wallis Anova).
Further examination revealed that the effect occurred as a conti-
nuum with acute-phase response over the entire patient group.
Indeed, the EBT 1/TMAX values negatively correlated with both
CRP and AAG with Spearman coefﬁcients of 70.64
(P50.00001) and 70.45 (P50.005), respectively. Weaker correla-
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Table 1 Patients’ demographics (n=40)
Characteristic n
Histology
Lung
a 19
Breast 9
Carcinoma of unknown primary 3
Head and neck 3
Others 6
ECOG performance status
04
12 1
21 2
33
Age (year)
30–50 7
51–65 14
66–90 19
aMostly non-small cell lung cancer.
Table 2 Base-line serum protein levels in study population (n=40)
Protein Median Range Reference range Units
Albumin 38.0 18–44 40–50 g l
71
Pre-albumin 0.22 0.05–0.39 0.17–0.35 g l
71
C-reactive protein 13.0 51–291 510 mg l
71
a1 acid glycoprotein 1.23 0.5–3.18 0.5–1.0 g l
71
Cytochrome P450 3A activity and cancer
LP Rivory et al
278
British Journal of Cancer (2002) 87(3), 277–280 ã 2002 Cancer Research UKtions were observed against albumin and pre-albumin (data not
shown). The EBT C20min was only correlated with pre-albumin
(Spearman coefﬁcient=0.38, P50.02). The distribution of the
CRP values appeared to be log-normal and log-CRP was signiﬁ-
cantly correlated with 1/TMAX as the independent variable
(r
2=0.44, P50.00002, Figure 1). In comparison, a similar regres-
sion with the C20min of the EBT yielded r
2=0.15 and P=0.012.
CRP serum levels were signiﬁcantly correlated with those of IL-6
(Spearman coefﬁcient=0.58, P50.0003) but not with any of the
other cytokines. Also, the CRP levels were signiﬁcantly different
across the ECOG performance status categories (Kruskal–Wallis,
P50.006, Figure 2). Because of the heterogeneous nature of the
population in terms of disease site, the correlation between CRP
and 1/TMAX was also examined in the sub-groups of breast and
lung cancer patients. The Spearman correlation values were
70.63 (P=0.07, n=9) and 70.53 (P50.02, n=19), respectively,
indicating that the effect is not likely to be tumour-type speciﬁc.
Co-medication may affect CYP3A activity either by induction or
inhibition. Examination of the treatment ﬁles of the patients in this
study revealed that three were being treated with inhibitors of
CYP3A (diltiazem and clarithromycin, respectively), while four
were on long-term treatment with the inducer dexamethasone
(daily doses 2–4 mg). The mean+s.d. of 1/TMAX for this latter
group was 0.073+0.028 min
71 as compared to the study average
of 0.057+0.024 min
71. The correlation between 1/TMAX and
CRP remained signiﬁcant even after removal of the data from
the seven patients on CYP3A-modifying medication (Spearman
Rho=70.55, P=0.002).
DISCUSSION
These results indicate that CYP3A function in patients with
advanced cancer is highly variable and correlates with markers of
the acute-phase response. Those patients with an acute-phase
response (CRP 410 mg l
71) had on average a 30% decrease in
their metabolic activity as compared to the control group. This
decrease in CYP3A activity with acute-phase response was best
detected using the recent 1/TMAX parameter of the erythromycin
breath-test, which is a better predictor of total drug clearance
(Rivory et al, 2001). However, similar trends occurred with the
C20min data, although these were not as signiﬁcant. One of the
disadvantages of using the C20min approach is that values of this
parameter are often signiﬁcantly different between male and female
subjects, possibly because of a ﬂawed assumption regarding CO2
output (Rivory et al, 2001). This phenomenon, however, was not
observed with our patient data. This suggests that the extreme
variability in CYP3A metabolism observed in cancer patients
obscures this possible bias.
The source of the variability in CYP3A function is not known
but our observation of a signiﬁcant correlation between acute-
phase response and the EBT 1/TMAX suggests that the pro-inﬂam-
matory cytokines, which are increased in malignancy (Heys et al,
1998; Barber et al, 1999; Martin et al, 1999), not only trigger the
acute-phase response but also result in compromised drug meta-
bolism by CYP3A in some cancer patients. The strong
correlation between the IL-6 and CRP serum levels is in strong
agreement with this interpretation, although other cytokines may
have contributed. In fact, the biological effect of cytokines is
modulated by complex inter-relationships with both their soluble
and membrane-bound receptors. We argue that serum CRP,
which is an indicator of hepatic gene regulation in the presence
of inﬂammatory cytokines, reﬂects the overall biological effect of
this inﬂammatory response.
AAG, which is one of the acute-phase reactants, was also
increased and there is the possibility that the EBT was modiﬁed
through the effects of protein-binding. Indeed, erythromycin is
highly bound to this protein (Prandota et al, 1980). In our study,
however, CRP was a more signiﬁcant predictor of CYP3A activity
than AAG. Also, it has been noted that the clearance of hepatically
metabolised drugs is sometimes reduced in xenograft-bearing
animals, even when these are not bound to AAG (Zamboni et al,
1998). Finally, there is evidence in support of a direct effect of
pro-inﬂammatory cytokines on CYP3A expression, activity and
drug clearance (Moreno et al, 1991; Craig et al, 1993; Chen et al,
1994; Muntane-Relat et al, 1995; Morgan, 1997; Pascussi et al,
2000).
The implications of this observation are many and of direct
relevance to the chemotherapy of cancer. Firstly, the variability
of CYP3A drug metabolism in cancer patients may justify the
need for doses to be ‘individualised’, using measures such as
the EBT (Hirth et al, 2000). Second, we found an association
between acute-phase response and poor performance status in
concert with other studies (O’Gorman et al, 1999). Hence, the
link between acute-phase response and impaired drug metabolism
may partly explain the observation of increased toxicity of drugs
in patients with poor performance status (Krikorian et al, 1978;
Freyer et al, 2000) although this is very likely a multi-factorial
phenomenon.
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Figure 1 The relationship between the 1/TMAX parameter of the
erythromycin breath test and serum C-reactive protein in 40 patients with
advanced cancer. The upper limit of normal of CRP is 10 mg l
71
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Figure 2 The distribution of the baseline serum C-reactive protein con-
centration in 40 cancer patients according to their performance status
(ECOG). Analysis according to Kruskal–Wallis Anova test indicates signiﬁ-
cant differences between the four groups (P50.006)
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